Articles From: Permian Basin Royalty Trust Announces July Cash Distribution to Pershing Square Submits Requisite Requests from Allergan Shareholders to Call Special Meeting


DALLAS , July 21, 2014 /PRNewswire/ -- Permian Basin Royalty Trust (NYSE: PBT) ("Permian") today declared a cash distribution to the holders of its units of beneficial interest of $0.118511 per unit, payable on August 14, 2014 , to unit holders of record on July 31, 2014 .
Sign-up for Permian Basin Royalty Trust Announces July Cash Distribution investment picks
DALLAS , June 20, 2014 /PRNewswire/ -- Permian Basin Royalty Trust (NYSE: PBT) ("Permian") today declared a cash distribution to the holders of its units of beneficial interest of $0.096581 per unit, payable on July 15, 2014 , to unit holders of record on June 30, 2014 .
Sign-up for Permian Basin Royalty Trust Announces June Cash Distribution investment picks
DALLAS , June 20, 2014 /PRNewswire/ -- Permian Basin Royalty Trust (NYSE: PBT) ("Permian") today announced that at the special meeting of the Trust's unitholders held today, the unitholders of the Trust voted to approve the proposal to appoint Southwest Bank as successor trustee to serve as trustee of the Trust once the resignation of the current Trustee of the Trust takes effect.
Sign-up for Permian Basin Royalty Trust Announces Results of Special Meeting investment picks
2014/6/23
Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Sanjay Patel as Chief Financial Officer.
Sign-up for Pernix Therapeutics Appoints Chief Financial Officer investment picks
2014/8/20
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet® (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults.
Sign-up for Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance. investment picks
Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the quarter and year-to-date periods ended June 30, 2014.
Sign-up for Pernix Therapeutics Reports Second Quarter 2014 Financial Results investment picks
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its second quarter 2014 financial results before the U.S. stock market opens on Monday, August 11, 2014 and has scheduled a conference call at 10:00 a.m. EDT that day to discuss the financial results.
Sign-up for Pernix Therapeutics to Report Second Quarter 2014 Financial Results on August 11, 2014 investment picks
CALGARY , June 25, 2014 /PRNewswire/ - (TSX:PMT) - Perpetual Energy Inc. ("Perpetual", or the "Company") is pleased to announce that it has entered into definitive agreements with a joint venture partner (the "JV Partner") for a portion of its lands in the Edson area of West Central Alberta (the "East Edson Property"). The joint venture ("East Edson JV") will significantly accelerate Perpetual's net production and funds flow growth from the East Edson Property.
Sign-up for Perpetual Energy Inc. Announces $120 Million Joint Venture in the East Edson Area and Gas Over Bitumen Royalty Credit Monetization, Reports Related Significant Positive Reserves Update and Provides Updated Guidance for 2014 and 2015 investment picks
Perpetual Energy Inc. announces upsizing and pricing of previously announced senior unsecured notes offering Canada NewsWire /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / CALGARY , July 18, 2014 /CNW/ - (TSX:PMT) - Perpetual Energy Inc. ("Perpetual" or the "Corporation") is pleased to announce the pricing of its offering of C$125 million aggregate principal amount of 8.75% Senior Unsecured Notes due July 23, 2019 (the "Notes") at par (the "Offering"), upsized from the previously announced C$100 million .
Sign-up for Perpetual Energy Inc. announces upsizing and pricing of previously announced senior unsecured notes offering investment picks
Perpetual Energy Inc. confirms closing of East Edson Joint Venture and announces intention to issue $100 million of Senior Unsecured Notes Canada NewsWire NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY , July 16, 2014 /CNW/ - (TSX:PMT) - Perpetual Energy Inc. ("Perpetual" or the "Company") is pleased to announce that it has successfully closed the previously announced East Edson Joint Venture (the "East Edson JV"). Proceeds to Perpetual include $50 million for the sale of a 50 percent gross overriding royalty on existing producing assets (the "Producing Royalty") and an additional $70 million to fund Wilrich development activities to earn a second royalty (the "Drilling Royalty"). In combination, in exchange for the total acquisition and funding commitment of $120 million , the Drilling and Producing Royalties entitle the joint venture partner to receive
Sign-up for Perpetual Energy Inc. confirms closing of East Edson Joint Venture and announces intention to issue $100 million of Senior Unsecured Notes investment picks
2014/8/7
Perpetual Energy Inc. Releases Second Quarter 2014 Financial and Operating Results Canada NewsWire Debt reduction and downside risk management On June 25, 2014 , Perpetual entered into a joint venture arrangement for the accelerated development of the Company's East Edson property.
Sign-up for Perpetual Energy Inc. Releases Second Quarter 2014 Financial and Operating Results investment picks
2014/7/8
DUBLIN , July 8, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg (over-the-counter), the store brand equivalent to Advil ® Congestion Relief Tablets, 200 mg/10 mg.
Sign-up for Perrigo Announces FDA Final Approval For The Store Brand Equivalent To Advil® Congestion Relief Tablets, 200 mg/10 mg investment picks
2014/6/20
DUBLIN , June 20, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) and its partner, Catalent, announced today that they have settled their first to file Hatch Waxman litigation with Teva with respect to a generic version of Proair® HFA.
Sign-up for Perrigo Announces Settlement In Proair® HFA Patent Case investment picks
2014/8/13
DUBLIN , Aug.
Sign-up for Perrigo Company plc Announces Quarterly Dividend investment picks
2014/7/31
DUBLIN , July 31, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its fourth quarter and fiscal year 2014 on Thursday, August 14, 2014 at approximately 8:00 a.m. (ET) .
Sign-up for Perrigo Company plc To Release Fourth Quarter And Fiscal Year 2014 Results On August 14, 2014 investment picks
DUBLIN , July 24, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it has received an AB therapeutic equivalent rating from the U.S. Food and Drug Administration (FDA) for its previously approved New Drug Application (NDA) for testosterone gel 1.0%. FDA concluded that Perrigo's testosterone product is therapeutically equivalent to [AbbVie's] AndroGel 1% and can be substituted with the full expectation that it will produce the same clinical effect and safety profile as AndroGel 1% when used under the conditions specified in the labeling.
Sign-up for Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% investment picks
DUBLIN , July 30, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for desoximetasone topical spray 0.25% and that it has notified Taro Pharmaceuticals U.S.A. , Inc., the owner of the Reference Listed Drug of its filing.
Sign-up for Perrigo Confirms First To File Patent Challenge For Generic Version Of Topicort® Topical Spray 0.25% investment picks
2014/8/21
Adjusted net loss per share of $0.08 better than guidance of an adjusted loss of $0.10 to $0.15 and represents a significant improvement from an adjusted net loss per share of $0.15 in the prior year second quarter.
Sign-up for Perry Ellis International Reports $2.5 Million Improvement in Operating Income for the Second Quarter of Fiscal 2015 investment picks
2014/8/13
Perry Ellis is seeing double in its Fall 2014 advertising campaign, which explores the dichotomies of men’s style and the versatility of the brand’s modern-yet-approachable collections.
Sign-up for Perry Ellis Launches Fall 2014 Advertising Campaign investment picks
CoreSite Realty Corporation (NYSE:COR), a provider of secure, reliable, high-performance data center solutions, today announced the availability of High Precision Time™, a new certified timing service by Perseus Telecom , within CoreSite’s Northern Virginia Market.
Sign-up for Perseus’ High Precision Time Service Now Available in CoreSite’s Northern Virginia Market investment picks
2014/7/9
Streamlined features bring advisors a new level of scalability, operational efficiency and transparency JERSEY CITY, N.J. , July 9, 2014 /PRNewswire/ -- Pershing LLC, a BNY Mellon company, today announced the next generation of its block trading and rebalancing tool—delivered through its technology platform NetX360 ® —which offers a series of new capabilities for advisors.
Sign-up for Pershing Announces the Next Generation of its Block Trading and Rebalancing Tool for Advisor-Directed Programs investment picks
2014/6/27
Pershing Square Capital Management, L.P. (“Pershing Square”) announced today it has entered into a settlement with Allergan, Inc. (“Allergan”) resolving to Pershing Square’s satisfaction the previously announced poison pill litigation before the Delaware Court of Chancery.
Sign-up for Pershing Square and Allergan Settle Delaware Court of Chancery Lawsuit Confirming that Allergan’s Rights Plan is Not Triggered by Efforts to Call a Special Meeting investment picks
2014/7/7
Pershing Square Capital Management, L.P. (“Pershing Square”) today announced a slate of six highly experienced, independent directors for the board of directors of Allergan, Inc. (“Allergan”). The six members of the slate are: Betsy Atkins, Cathleen P.
Sign-up for Pershing Square Proposes Independent Slate For Allergan Board of Directors investment picks
2014/7/16
Pershing Square Capital Management, L.P. (“Pershing Square”) today announced it has sent a letter to Allergan, Inc. (“Allergan”)’s Board of Directors.
Sign-up for Pershing Square Releases Letter to Allergan’s Board of Directors investment picks
Pershing Square Capital Management, L.P. (“Pershing Square”), the largest shareholder of Allergan, Inc. (NYSE:AGN) (“Allergan”), announced that on Friday it submitted to Allergan additional special meeting requests from shareholders owning approximately 0.6% of Allergan’s shares.
Sign-up for Pershing Square Submits Additional Special Meeting Requests investment picks
Pershing Square Capital Management, L.P. (“Pershing Square”), the largest shareholder of Allergan, Inc. (NYSE:AGN) (“Allergan”), announced today that it has submitted additional special meeting requests from shareholders owning 1.29% of Allergan’s shares, bringing the total to 35.1%. Not including Pershing Square, shareholders owning over 25% of Allergan’s shares have now provided the necessary documentation and cleared the administrative hurdles in Allergan’s bylaws to join Pershing Square in calling for the special meeting.
Sign-up for Pershing Square Submits Additional Special Meeting Requests Representing 35% of Allergan Shares investment picks
Pershing Square Capital Management, L.P. (“Pershing Square”), the largest shareholder of Allergan, Inc. (NYSE:AGN) (“Allergan”), announced today that it submitted the required documentation to compel Allergan to call a special meeting of Allergan shareholders.
Sign-up for Pershing Square Submits Requisite Requests from Allergan Shareholders to Call Special Meeting investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Permian Basin Royalty Trust Announces July Cash Distribution to Pershing Square Submits Requisite Requests from Allergan Shareholders to Call Special Meeting
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices